HSC-targeted delivery of shRNA-TGFβ1 by vitamin A-functionalized polyaminoglycoside for hepatic fibrosis therapy
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Liver physiology and pathology · Liver Disease Diagnosis and Treatment · Organ Transplantation Techniques and Outcomes
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (49)
Show source-provided references
1. Targeting fibrosis, mechanisms and cilinical trials10.1038/s41392-022-01070-3 ↗
2. Mechanisms of liver fibrosis and its role in liver cancer10.1177/1535370219898141 ↗
3. Efficient drug and gene delivery to liver fibrosis: rationale, recent advances, and perspectives10.1016/j.apsb.2020.03.007 ↗
4. Targeting metabolic dysregulation for fibrosis therapy10.1038/s41573-019-0040-5 ↗
5. Fibrosis: from mechanisms to medicines10.1038/s41586-020-2938-9 ↗
6. Molecular and cellular mechanisms of liver fibrosis and its regression10.1038/s41575-020-00372-7 ↗
7. Nintedanib with add-on pirfenidone in idiopathic pulmonary fibrosis. Results of the INJOURNEY trial10.1164/rccm.201706-1301OC ↗
8. Leveraging ageing models of pulmonary fibrosis: the efficacy of nintedanib in ageing10.1183/13993003.00759-2021 ↗
9. Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases10.1183/13993003.00161-2019 ↗
10. South-West of England's experience of the safety and tolerability pirfenidone and nintedanib for the treatment of idiopathic pulmonary fibrosis (IPF)10.3389/fphar.2018.01480 ↗
11. Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trials10.1016/S2213-2600(18)30185-1 ↗
12. Mechanisms of hepatic stellate cell activation10.1038/nrgastro.2017.38 ↗
13. Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues10.1016/j.mam.2018.09.002 ↗
14. Hepatic inflammation and fibrosis: functional links and key pathways10.1002/hep.27332 ↗
15. The stellate cell system (vitamin A-storing cell system)10.1007/s12565-017-0395-9 ↗
16. Corona-directed nucleic acid delivery into hepatic stellate cells for liver fibrosis therapy10.1021/nn505166x ↗
17. Synergistic MicroRNA therapy in liver fibrotic rat using MRI-visible nanocarrier targeting hepatic stellate cells10.1002/advs.201801809 ↗
18. Vitamin A-coupled stem cell-derived extracellular vesicles regulate the fibrotic cascade by targeting activated hepatic stellate cells in vivo10.1016/j.jconrel.2021.06.031 ↗
19. TGF-β signaling pathway as a pharmacological target in liver diseases10.1016/j.phrs.2014.05.005 ↗
20. Pien-Tze-Huang alleviates CCl(4)-induced liver fibrosis through the inhibition of HSC autophagy and the TGF-β1/Smad2 pathway
21. Transforming growth factor-β-induced cell plasticity in liver fibrosis and hepatocarcinogenesis10.3389/fonc.2018.00357 ↗
22. TGF-β in hepatic stellate cell activation and liver fibrogenesis-updated 201910.3390/cells8111419 ↗
23. Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosis10.1172/JCI73722 ↗
24. Regulation of barrier immunity and homeostasis by integrin-mediated transforming growth factor β activation10.1111/imm.13162 ↗
25. Transforming growth factor β neutralization ameliorates pre-existing hepatic fibrosis and reduces cholangiocarcinoma in thioacetamide-treated rats10.1371/journal.pone.0054499 ↗
26. Human monocytes and macrophages regulate immune tolerance via integrin αvβ8-mediated TGFβ activation10.1084/jem.20171491 ↗
27. siRNA- and miRNA-based therapeutics for liver fibrosis10.1016/j.trsl.2019.07.007 ↗
28. Molecularly engineered siRNA conjugates for tumor-targeted RNAi therapy10.1016/j.jconrel.2022.09.040 ↗
29. In vivo gene therapy to the liver and nervous system: promises and challenges
30. Delivery of matrix metalloproteinase-1 attenuates established liver fibrosis in the rat10.1053/gast.2003.50063 ↗
31. New gene therapy strategies for hepatic fibrosis10.3748/wjg.v21.i13.3813 ↗
32. AAV vector integration sites in mouse hepatocellular carcinoma10.1126/science.1142658 ↗
33. Polyaminoglycoside-mediated cell reprogramming system for the treatment of diabetes mellitus10.1016/j.jconrel.2022.01.041 ↗
34. Phenylboronic acid-functionalized polyaminoglycoside as an effective CRISPR/Cas9 delivery system10.1039/D1BM00185J ↗
35. Reduction-responsive multifunctional hyperbranched polyaminoglycosides with excellent antibacterial activity, biocompatibility and gene transfection capability10.1016/j.biomaterials.2016.08.025 ↗
36. A hybrid nanovector of suicide gene engineered lentivirus coated with bioreducible polyaminoglycosides for enhancing therapeutic efficacy against glioma10.1002/adfm.201900922 ↗
37. Simultaneous analysis of water-soluble and fat-soluble vitamins through RP-HPLC/DAD in food supplements and brewer's yeast10.1016/j.heliyon.2022.e12706 ↗
38. The proton sponge hypothesis: Fable or fact?10.1016/j.ejpb.2018.05.034 ↗
39. The great escape: how cationic polyplexes overcome the endosomal barrier10.1039/C8TB00967H ↗
40. Bioreducible Zinc(II)-coordinative polyethylenimine with low MOlecular Weight for Robust Gene Delivery of Primary and Stem Cells10.1021/jacs.6b13337 ↗
41. Effects of vitamin A on the erythrocyte membrane surface10.1182/blood.V41.6.893.893 ↗
42. Advances in the research of nanodrug delivery system for targeted treatment of liver fibrosis10.1016/j.biopha.2021.111342 ↗
43. Endothelial GATA4 controls liver fibrosis and regeneration by preventing a pathogenic switch in angiocrine signaling10.1016/j.jhep.2020.08.033 ↗
44. MicroRNA-378 limits activation of hepatic stellate cells and liver fibrosis by suppressing Gli3 expression10.1038/ncomms10993 ↗
45. SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis10.1038/s41467-019-14138-6 ↗
46. Multi-scale information with attention integration for classification of liver fibrosis in B-mode US image10.1016/j.cmpb.2021.106598 ↗
47. Ultrasonographic analyses of the forehead region for injectable treatments10.1016/j.ultrasmedbio.2019.06.414 ↗
48. Effects of fibrotic tissue on liver-targeted hydrodynamic gene delivery
49. AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury10.1002/hep.32689 ↗